The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
"Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring."
The seed round was led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp to fund team expansion and product development.
"The pharmaceutical industry has made tremendous strides in AI for hit identification and lead optimisation, but target safety assessment has lagged behind. Sable is positioned to change that by making comprehensive safety data accessible and actionable. We’re thrilled that with this funding, we can build the definitive platform for drug target safety."
The biotechnology funding pairs strategic capital with a collaborative agreement to explore oncology opportunities.
"This strategic investment is an important endorsement of AMPLY's platform and our approach to oncology. We're building a company designed for partnering – generating high-quality, data-driven programmes and taking them to clear inflection points. We're delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness."
The seed round was led by XTX Ventures to expand team capacity and boost production capabilities.
"Across the different chemical industries everyone wants to be more efficient and produce the compounds society needs quicker, despite the challenges industry faces. We are helping pharmaceutical, agrochemical, and specialty chemical companies do just that."
.png)
